Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Choosing the right credit card can unlock amazing bonuses. Explore the options that offer the best rewards for your spending habits.
24,052 articlesInvestors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
A notable insider transaction at REX raised questions for investors. This guide explains what investors should know, ...
Dylan Lee’s wedding in Saint-Tropez blends private moments with luxury, offering practical budgeting insights for cou...
Meta is testing a bold cloud strategy that could reshape its growth trajectory. This article breaks down how leasing ...
As market volatility persists in mid-2026, five high-quality dividend stocks appear especially compelling for income ...
Cathie Wood’s big bet on CRISPR Therapeutics signals more than faith in gene editing. This article digs into the unde...
In a bold move amid 13F season, investor Gavin Baker places a major levered bet on Nvidia through call options, signa...
Kick off your week with a focused investing routine. This article shares 10 Tuesday AM Reads you can digest in 15 min...
River Road Asset Management just added a notable new position in AptarGroup, acquiring 917,670 shares valued at about...
Two next-gen income ETFs are quietly beating JEPI in 2026, driven by selective options writing and global dividend ex...
Investors are eyeing CAVA as a potential hit in fast casual. This article weighs growth prospects, unit economics, an...
With volatility cooling, investors are turning to dividend-focused names. Three no-brainer high-yielding stocks with ...